Oncotarget

Research Papers:

Genomic mutations and histopathologic biomarkers in Y90 radioembolization for chemorefractory colorectal liver metastases

Meaghan S. Dendy, Johannes M. Ludwig, Nima Kokabi, Stacey M. Stein, Jill Lacy, Howard S. Hochster and Hyun S. Kim _

PDF  |  HTML  |  How to cite  |  Press Release  |  Order a Reprint

Oncotarget. 2018; 9:32523-32533. https://doi.org/10.18632/oncotarget.25992

Metrics: PDF 478 views  |   HTML 1799 views  |   ?  


Abstract

Meaghan S. Dendy1, Johannes M. Ludwig1,2, Nima Kokabi1,3, Stacey M. Stein4,5, Jill Lacy4,5, Howard S. Hochster6 and Hyun S. Kim1,4,5

1Division of Interventional Radiology, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA

2Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

3Division of Interventional Radiology and Image Guided Medicine, Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, USA

4Division of Medical Oncology, Department of Medicine, Yale School of Medicine, New Haven, CT, USA

5Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA

6Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

Correspondence to:

Hyun S. Kim, email: kevin.kim@yale.edu

Keywords: radioembolization; CRC; biomarker; colorectal liver metastases; CRLM

Received: January 04, 2018     Accepted: August 02, 2018     Published: August 21, 2018

ABSTRACT

Background: To investigate mutational load and histologic biomarkers as prognostic factors in patients with chemorefractory colorectal liver metastases (CRLM) treated with Y-90 radioembolization therapy.

Materials and Methods: Single institution retrospective study of patients with CRLM who received Y-90 radioembolization after undergoing molecular testing was performed. Patient demographics, systemic therapy regimens, tumor characteristics and overall survival were analyzed between patients with differing histopathologic and genomic status. PIK3CA, KRAS, NRAS, AKT1, MEK1, MLH1, MSH2, MSH6 and PMS2 were analyzed. Kaplan-Meier survival estimation and multivariate Cox regression were analyzed.

Results: 23 patients underwent genomic analysis prior to Y-90. Eleven (47.8%) had mutations identified (MUT), and 12 were sequenced as wild type (WT) (52.2%). Median OS of 23 patients after Y-90 was 9.6 months (95% CI 6.67-16.23). Median OS from first Y-90 was significantly greater in WT patients (16.2 mo vs 6.5 mo; p =.0054). The survival difference between poorly differentiated tumors compared to all other histologic grades was significant (poor vs. well p=0.025, HR=26.8; poor vs. moderate p=.014, HR=23.07; poor vs. moderate/poor p=0.014, HR=23.68). When separated into 3 different groups (WT vs. MUT/moderate differentiation vs. MUT/poor differentiation) there was a difference in median OS observed (16.2 vs. 8.0 vs. 3.8 mos; p<.0001). Imaging response via RECIST criteria was significantly different between MUT and WT groups (p=0.02).

Conclusions: Mutational status and histopathologic grade may predict survival after Y-90 radioembolization therapy for CRLM.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25992